Cargando…

Canada's Patented Medicine Notice of Compliance regulations: balancing the scales or tipping them?

BACKGROUND: In order to comply with the provisions of the North American Free Trade Agreement, in 1993 the Canadian federal government introduced the Patented Medicine Notice of Compliance Linkage Regulations. These regulations were meant to achieve a balance between the timely entry of generic medi...

Descripción completa

Detalles Bibliográficos
Autor principal: Lexchin, Joel
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073891/
https://www.ncbi.nlm.nih.gov/pubmed/21435247
http://dx.doi.org/10.1186/1472-6963-11-64
_version_ 1782201654406283264
author Lexchin, Joel
author_facet Lexchin, Joel
author_sort Lexchin, Joel
collection PubMed
description BACKGROUND: In order to comply with the provisions of the North American Free Trade Agreement, in 1993 the Canadian federal government introduced the Patented Medicine Notice of Compliance Linkage Regulations. These regulations were meant to achieve a balance between the timely entry of generic medicines and the rights of patent holders. The regulations tied the regulatory approval of generic medicines to the patent status of the original brand-name product. DISCUSSION: Since their introduction the regulations have been a source of contention between the generic and the brand-name industry. While the regulations have generated a considerable amount of work for the Federal Court of Canada both sides dispute the interpretation of the "win rate" in the court cases. Similarly, there is no agreement on whether multiple patents on single drugs represent a legitimate activity by the brand-name industry or an "evergreening" tactic. The generic industry's position is that the regulations are being abused leading to the delay in the introduction of lower cost generic products by as much as 8 years. The brand-name companies counter that the regulations are necessary because injunctions against the introduction of generic products are frequently unavailable to them. The regulations were amended in 2006 and again in 2008 but both sides continue to claim that the regulations favour the other party. The battle around the regulations also has an international dimension with interventions by PhRMA, the trade association representing the United States based multinational companies, arguing that the regulations are not stringent enough and that Canada needs to be placed on the U.S. Priority Watch List of countries. Finally, there are multiple costs to Canadian society as a result of the NOC regulations. SUMMARY: Despite the rhetoric there has been almost no empiric academic research done into the effect of the regulations. In order to develop rational policy in this area a number of key research questions have been formulated.
format Text
id pubmed-3073891
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-30738912011-04-12 Canada's Patented Medicine Notice of Compliance regulations: balancing the scales or tipping them? Lexchin, Joel BMC Health Serv Res Debate BACKGROUND: In order to comply with the provisions of the North American Free Trade Agreement, in 1993 the Canadian federal government introduced the Patented Medicine Notice of Compliance Linkage Regulations. These regulations were meant to achieve a balance between the timely entry of generic medicines and the rights of patent holders. The regulations tied the regulatory approval of generic medicines to the patent status of the original brand-name product. DISCUSSION: Since their introduction the regulations have been a source of contention between the generic and the brand-name industry. While the regulations have generated a considerable amount of work for the Federal Court of Canada both sides dispute the interpretation of the "win rate" in the court cases. Similarly, there is no agreement on whether multiple patents on single drugs represent a legitimate activity by the brand-name industry or an "evergreening" tactic. The generic industry's position is that the regulations are being abused leading to the delay in the introduction of lower cost generic products by as much as 8 years. The brand-name companies counter that the regulations are necessary because injunctions against the introduction of generic products are frequently unavailable to them. The regulations were amended in 2006 and again in 2008 but both sides continue to claim that the regulations favour the other party. The battle around the regulations also has an international dimension with interventions by PhRMA, the trade association representing the United States based multinational companies, arguing that the regulations are not stringent enough and that Canada needs to be placed on the U.S. Priority Watch List of countries. Finally, there are multiple costs to Canadian society as a result of the NOC regulations. SUMMARY: Despite the rhetoric there has been almost no empiric academic research done into the effect of the regulations. In order to develop rational policy in this area a number of key research questions have been formulated. BioMed Central 2011-03-24 /pmc/articles/PMC3073891/ /pubmed/21435247 http://dx.doi.org/10.1186/1472-6963-11-64 Text en Copyright ©2011 Lexchin; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Debate
Lexchin, Joel
Canada's Patented Medicine Notice of Compliance regulations: balancing the scales or tipping them?
title Canada's Patented Medicine Notice of Compliance regulations: balancing the scales or tipping them?
title_full Canada's Patented Medicine Notice of Compliance regulations: balancing the scales or tipping them?
title_fullStr Canada's Patented Medicine Notice of Compliance regulations: balancing the scales or tipping them?
title_full_unstemmed Canada's Patented Medicine Notice of Compliance regulations: balancing the scales or tipping them?
title_short Canada's Patented Medicine Notice of Compliance regulations: balancing the scales or tipping them?
title_sort canada's patented medicine notice of compliance regulations: balancing the scales or tipping them?
topic Debate
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073891/
https://www.ncbi.nlm.nih.gov/pubmed/21435247
http://dx.doi.org/10.1186/1472-6963-11-64
work_keys_str_mv AT lexchinjoel canadaspatentedmedicinenoticeofcomplianceregulationsbalancingthescalesortippingthem